MODEL VERDICT
Connect Biopharma Holdings Limited (CNTB)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 182 industry peers | $5.67 | +108.5% | 4% | B | Data |
| Price / Sales 184 industry peers | $4.00 | +47.1% | 3% | B | Model Driven |
| Weighted Output Blended model output | $4.66 | +71.3% | 100% | 49 | SIGNIFICANTLY UNDERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 0.82 | 0.83 | 0.64 | 0.99 | 0.17 |
| P/B Ratio | 0.82 | 0.83 | 0.64 | 0.99 | 0.17 |
Based on our peer multiples analysis with 4 valuation metrics, the model estimates CNTB's fair value at $4.66 vs the current price of $2.72, implying +71.3% upside potential. Model verdict: Significantly Undervalued. Confidence: 49/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $4.66 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $2.79 (P10) to $7.23 (P90), with a median of $4.95.
CNTB's current P/E of -9.7x compares to the industry median of 23.5x (45 peers in the group). This represents a -141.4% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
5 analysts cover CNTB with a consensus rating of Buy. The consensus price target is $9.00 (range: $9.00 — $9.00), implying +230.9% upside from the current price. Grade breakdown: Strong Buy (0), Buy (4), Hold (1), Sell (0), Strong Sell (0).
The model confidence score is 49/100, based on: data completeness (6), peer quality (25), historical depth (10), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for CNTB.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.